Sequence Bio
Discovering the true signals of disease to power life-changing medicines
Sequence Bio is a data-driven biotechnology company based in Newfoundland and Labrador, Canada. It leverages the unique genetic characteristics of the region's founder population, combined with multi-omics data and real-world patient records, to accelerate disease target discovery. The company aims to enable the development of better medicines faster by identifying low-frequency, high-impact genetic variants linked to disease.
Sequence Bio uses the founder population of Newfoundland and Labrador — which has less genetic variation — combined with complete health records and multi-omics data to efficiently discover high-impact disease variants.
Pharmaceutical and biotech companies seeking novel drug targets
Background.
- Status
- launched
- Business model
- unknown
- Company
- Sequence Bio
Similar projects.
Editorial take on the space this project sits in — momentum signals, adjacent moves, our call on whether the wedge is real. Get pinged when we publish a new read or when the landscape shifts.
Have a take on this space?
Tell us what you’d build differently, where you think the incumbents miss, or what we’ve gotten wrong about this project. Comments + reactions are coming soon.